Eris Lifesciences Ltd
ERISBSE 540596PharmaceuticalsMkt cap ₹16,508 Cr
Whole group, including subsidiaries — the figures companies headline.
Revenue · Q1 FY27
₹873 Cr
YoY +13.0%QoQ +15.4%
Net profit · Q1 FY27
₹143 Cr
YoY +14.6%QoQ -48.6%
Net margin · Q1 FY27
16.4%
+0.2 pts vs Q1 FY26
Net profit · FY26
₹648 Cr
YoY +72.8%
Quarterly results
| ₹ Cr | Q1 FY27 Apr–Jun 2026 | Q4 FY26 Jan–Mar 2026 | Q3 FY26 Oct–Dec 2025 | Q2 FY26 Jul–Sep 2025 | Q1 FY26 Apr–Jun 2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | 873 | 757 | 807 | 792 | 773 | +13.0% |
| Other income | 2.39 | 2.23 | 0.02 | 2.81 | 2.69 | -11.2% |
| Total income | 876 | 759 | 807 | 795 | 776 | +12.9% |
| Profit before tax | 180 | 161 | 145 | 172 | 160 | +12.3% |
| Tax | 36.17 | -120 | 36.52 | 38.20 | 36.00 | +0.5% |
| Net profit | 143 | 279 | 109 | 134 | 125 | +14.6% |
| Net margin | 16.4% | 36.9% | 13.5% | 17.0% | 16.2% |
Annual results
| ₹ Cr | FY26 Apr 2025–Mar 2026 | FY25 Apr 2024–Mar 2025 | FY24 Apr 2023–Mar 2024 | FY23 Apr 2022–Mar 2023 | FY22 Apr 2021–Mar 2022 | YoY |
|---|---|---|---|---|---|---|
| Revenue | 3,129 | 2,894 | 2,009 | 1,685 | 1,347 | +8.1% |
| Other income | 7.75 | 18.36 | 23.82 | 11.15 | 26.09 | -57.8% |
| Total income | 3,137 | 2,912 | 2,033 | 1,696 | 1,373 | +7.7% |
| Profit before tax | 638 | 489 | 431 | 405 | 442 | +30.6% |
| Tax | -8.97 | 114 | 34.18 | 30.48 | 36.41 | -107.9% |
| Net profit | 648 | 375 | 397 | 374 | 406 | +72.8% |
| Net margin | 20.7% | 12.9% | 19.8% | 22.2% | 30.1% |
BIC's take
We haven't covered Eris Lifesciences Ltd yet. Browse our sector reports →
Source: BSE filings · Data as of 2 Oct 2026, 6:58 pm IST· ₹ crore unless stated. Covers BSE 500 companies only. Consolidated figures include subsidiaries; standalone is the parent company alone. Growth is shown only against a positive base. Not investment advice — check the company's full filing before acting.